Channels of Communication & Brain Functioning: Pilot fMRI Study
NCT ID: NCT04533126
Last Updated: 2020-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2020-09-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this work, it will be examined how different communication modalities cause different reactions in a person. We make the assumption that each communication modality is based on a different brain network.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* In the prescriptive channel, the interlocutor should be firm and determined, without being aggressive.
* The informative/interrogative channel requires a neutral tone of voice, showing no particular emotion. The interlocutor should emphasize using questions as a tool to communicate with the person.
* The ludic/emotive channel emphasizes exclamations, interjections, and allows expressing one's desires and urges, with immediate reactions without thinking them twice.
* The fostering channel allows sharing one's emotions and feelings with the interlocutor in a close, warm, and caring way.
These channels refer to both the used words and to the non-verbal part of communication (gestures, mimic, tone of voice).
This study aims to characterize the brain regions involved in the response to the different channels of communication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both sexes (1:1).
3. Aged between 20 and 30 years old.
4. Medical student, from L2.
5. A person who has signed a written, free and informed consent.
6. Person affiliated to a social security scheme.
Exclusion Criteria
2. Current or past neurological disorder with current functional impact.
3. Chronic unstable somatic pathology.
4. Occasional use of medication other than contraceptives, migraine medication, or analgesics.
5. MRI contraindications, including claustrophobia.
6. Pregnant or breastfeeding woman.
7. Subject deprived of liberty (by a judicial or administrative decision).
8. Subject protected by law (subject under guardianship and curatorship).
9. Legal incapacity and/or other circumstances rendering the subject incapable of understanding the nature, purpose or consequences of the study.
10. A person participating in a clinical drug study or in a period of exclusion from any clinical study due to previous participation.
20 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kahler Communication France
UNKNOWN
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GISSOT Valérie, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU Tours - CIC1415
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Investigation Clinique
Tours, Centre-Val de Loire, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Valérie Gissot
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHAO20-WEH-COCACE (DR200102)
Identifier Type: -
Identifier Source: org_study_id